Holen Sie sich die Stockscreener-App
0.6994
0.66%
0.0046
Handel nachbörslich:
.68
-0.0194
-2.77%
Schlusskurs vom Vortag:
$0.6948
Offen:
$0.7068
24-Stunden-Volumen:
269.46K
Relative Volume:
0.28
Marktkapitalisierung:
$41.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.27
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
-7.97%
1M Leistung:
+1.67%
6M Leistung:
+43.85%
1J Leistung:
-63.57%
1-Tages-Spanne:
$0.674
$0.7202
1-Wochen-Bereich:
$0.6611
$0.80
52-Wochen-Spanne:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.6994 | 40.80M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
Is BioAtla Inc. a candidate for recovery play2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Sentiment analysis tools applied to BioAtla Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
What to do if you’re stuck in BioAtla Inc.Earnings Growth Report & Technical Pattern Recognition Alerts - newser.com
Will BioAtla Inc. continue its uptrendRate Hike & Safe Entry Point Alerts - newser.com
Why BioAtla Inc. stock is favored by top institutions2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsLayoff News & Verified Short-Term Plans - newser.com
How supply chain issues affect BioAtla Inc. stockAnalyst Upgrade & Weekly High Conviction Ideas - newser.com
Chart overlay techniques for tracking BioAtla Inc.Gold Moves & Low Drawdown Trading Strategies - newser.com
Measuring BioAtla Inc.’s beta against major indicesWeekly Trade Report & Weekly High Potential Stock Alerts - newser.com
What moving averages say about BioAtla Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Why BioAtla Inc. stock is a value investor pickWeekly Risk Summary & Advanced Technical Signal Analysis - Fundação Cultural do Pará
BioAtla’s Phase 1 Study on BA3182: A New Hope for Advanced Adenocarcinoma - TipRanks
Can BioAtla Inc. stock sustain institutional interest2025 Big Picture & Capital Protection Trade Alerts - Fundação Cultural do Pará
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):